SCHEMBL15099694

SCHEMBL15099694

CCOC(=O)[C@@H](O)c1c(C)cc2cc(C)ccc2c1OS(=O)(=O)C(F)(F)F

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 5/20 0.33
HPGD P15428 5/20 0.33
MAPK1 P28482 4/20 0.33
KMT2A Q03164 4/20 0.33
MAPT P10636 3/20 0.33
TP53 P04637 3/20 0.33
NPSR1 Q6W5P4 3/20 0.33
TLR9 Q9NR96 3/20 0.33
RAB9A P51151 2/20 0.33
BCL2A1 Q16548 2/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
HTT P42858 2/20 0.33
KDM4E B2RXH2 4/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ADORA1 P30542 1/20 0.32
ALDH1A1 P00352 4/20 0.32
LMNA P02545 3/20 0.31
ALOX15 P16050 1/20 0.31
BID P55957 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15093263 1.00 HSD17B10 (0.33) HSD17B10HPGDMAPK1KMT2AMAPT
SCHEMBL15099758 0.90 SMN1; SMN2 (0.36) HSD17B10HPGDMAPK1KMT2AMAPT
SCHEMBL15093724 0.90 SMN1; SMN2 (0.36) HSD17B10HPGDMAPK1KMT2AMAPT
SCHEMBL16657257 0.90 SMN1; SMN2 (0.36) HSD17B10HPGDMAPK1KMT2AMAPT
SCHEMBL16657250 0.89 CXCR2 (0.34) HSD17B10HPGDMAPK1KMT2AMAPT
SCHEMBL15093485 0.89 CXCR2 (0.32) ALDH1A1
SCHEMBL1699632 0.88 HSD17B10 (0.38) HSD17B10HPGDMAPK1KMT2AMAPT
SCHEMBL10271718 0.88 HSD17B10 (0.38) HSD17B10HPGDMAPK1KMT2AMAPT
SCHEMBL15099649 0.86 MAPT (0.32) HSD17B10HPGDMAPK1KMT2AMAPT
SCHEMBL15093787 0.86 MAPT (0.32) HSD17B10HPGDMAPK1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9284323-B2 Naphthalene acetic acid derivatives against HIV infection GILEAD SCIENCES, INC. (US) 2016-03-15 US disclosed
US-20150111891-A1 NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION GILEAD SCIENCES, INC. (US) 2015-04-23 US disclosed
US-20150111891-A1 NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION GILEAD SCIENCES, INC. (US) 2015-04-23 US disclosed
WO-2013103738-A1 NAPTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION GILEAD SCIENCES, INC. (US) 2013-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150111891-A1 NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION NFATC1, ACIN1, NAAA HSD17B10 268/4885HPGD 328/4885MAPK1 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.